CD8A and adult T-cell leukemia/lymphoma: In view of this patient’s exceptional response and preclinical results suggesting that 9-ING-41 promotes immune activation of CD8 + T cells, an expansion cohort of patients with refractory ATLL was added to the ongoing Phase 1/2 study of 9-ING-41.